Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases

  • US 7,445,802 B2
  • Filed: 12/26/2001
  • Issued: 11/04/2008
  • Est. Priority Date: 12/26/2000
  • Status: Expired due to Fees
First Claim
Patent Images

1. A conjugate of alliinase, in an enzymatically active form, with an antibody, wherein said conjugate binds to a cell or to a microorganism of interest in the body of a mammal.

View all claims

    Thank you for your feedback